Should I Buy SLXN? SLXN 2026 Analysis

Should You Buy Silexion Therapeutics Corp (SLXN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.960

1 Day change

-3.92%

52 Week Range

36.000

Analysis Updated At

2026/01/26

Silexion Therapeutics Corp (SLXN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company's financial performance is weak, with significant losses and no revenue growth. While the analyst rating is positive with a $6 price target, the lack of recent news, neutral trading trends, and no proprietary trading signals suggest limited immediate upside. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on investing in SLXN is recommended until stronger catalysts or financial improvements emerge.

Technical Analysis

The MACD is positive but contracting, indicating a weakening bullish momentum. RSI is neutral at 48.561, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 2.228, with resistance at 2.473 and support at 1.984.

Options Data

Positive Catalysts

Positive analyst rating with a $6 price target and potential late-stage clinical development for unmet needs in KRAS-driven cancers.

Neutral/Negative Catalysts

Weak financial performance with significant losses in net income and EPS. No recent news or significant trading trends from insiders or hedge funds. No proprietary trading signals or congress trading data.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income dropped by -72.50% YoY to -$3,262,000, and EPS declined by -97.99% YoY to -2.88. Gross margin remained at 0.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Litchfield Hills analyst initiated coverage with a Buy rating and a $6 price target, citing the company's innovative siRNA platform and potential late-stage clinical development.

2 Analyst Rating

Wall Street analysts forecast SLXN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLXN is 9 USD with a low forecast of 6 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.040

Low

Averages

High

Current: 2.040

Low

Averages

High

Litchfield Hills

Theodore O'Neill

Buy

initiated

AI Analysis

2025-12-15

Reason

Litchfield Hills

Theodore O'Neill

Price Target

AI Analysis

2025-12-15

initiated

Buy

Reason

Litchfield Hills analyst Theodore O'Neill initiated coverage of Silexion Therapeutics with a Buy rating and $6 price target. Silexion Therapeutics is targeting unmet need in KRAS-driven cancers and its siRNA platform takes a fundamentally different approach from current KRAS-targeted therapies, the analyst tells investors. The company is positioned to enter late-stage clinical development, with regulatory submission to the Israel Ministry of Health in Q4 followed by filings in Germany and the broader European Union in Q1, the analyst noted.

Maxim Group

Naz Rahman

Strong Buy

Maintains

$9 → $5

2025-03-20

Reason

Maxim Group

Naz Rahman

Price Target

$9 → $5

2025-03-20

Maintains

Strong Buy

Reason

Maxim lowered the firm's price target on Silexion Therapeutics to $5 from $9 and keeps a Buy rating on the shares after its Q4 results. The company is progressing with its SIL-204, an updated formulation of its prior LODER therapy, a KRAS targeting siRNA therapy for treating non-resectable, locally advanced pancreatic cancer, though the firm is reducing its price target due to the additional dilution from the recent capital raise and warrant exercises, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SLXN

Unlock Now

SLXN Should I Buy

SLXN Should I Buy

Should You Buy Silexion Therapeutics Corp (SLXN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch